Cvs Health Corp - CVS STOCK NEWS

CVS Health (NYSE: CVS) has announced it will host its first quarter 2025 earnings conference call on Thursday, May 1st, 2025, at 8:00 a.m. ET. The event will include discussions of Q1 2025 financial results with analysts and investors. An audio webcast will be available simultaneously on the company's Investor Relations website at investors.cvshealth.com, where it will remain accessible for one year.

CVS Health (NYSE: CVS) has announced its board of directors' approval of a quarterly dividend of $0.665 per share on the company's Common Stock. The dividend will be distributed to shareholders of record as of April 22, 2025, with the payment scheduled for May 1, 2025.

CVS Health (NYSE: CVS) has released data from its CVS Weight Management™ program, showing participants achieved over 15% average weight loss. The program, now available to 3.5 million CVS Caremark plan members, combines one-on-one support from registered dietitians with personalized nutrition planning in a virtual setting.

Key findings reveal that CVS Caremark clients adopting the program spent up to 26% less on GLP-1 medications compared to non-adopting clients. The program demonstrated remarkable results: members who previously lost less than 1% body weight on anti-obesity medication achieved an average 11.7% weight loss after enrollment - a 13x increase. Additionally, those with moderate pre-program success reached an average 20% weight loss.

The program maintains a 92% satisfaction rate after six months, and notably, members who discontinued anti-obesity medication while maintaining lifestyle support retained 94% of their weight loss. These results are based on data from 265,000 members during 2023-2024.

CVS Health Foundation has announced a $2 million Health Zones funding to support the Hispanic Health Council's Family Wellness Center and its partners in Hartford, Connecticut. The initiative aims to address healthcare barriers for individuals with chronic health conditions, serving a state where over 2 million residents live with such conditions.

The funding will enable the Hispanic Health Council to hire three new patient navigators and provide comprehensive services including preventative care, nutrition counseling, mental health support, and community health education. Partner organizations include Mental Health Connecticut and the Villages for Families and Children.

Additionally, CVS Health offered free health screenings through its Project Health initiative, which screened over 450 participants resulting in 1,500+ screenings in Hartford last year. The program will be available in Hartford from June 3 to June 28.

Wellvana has acquired CVS Health's Medicare Shared Savings Program (MSSP) business in an all-stock transaction, resulting in CVS Health obtaining a strategic minority stake in Wellvana. The acquisition positions Wellvana as one of the largest value-based care enablement companies, now supporting healthcare providers across 40 states and serving approximately 1 million Medicare patients.

The combined entity has generated hundreds of millions in Medicare program savings over the past decade. The deal enhances Wellvana's capabilities by expanding its ACO presence, broadening its hospital and physician network, and adding expertise from CVS Health's MSSP business. Physicians joining Wellvana's network will gain access to scheduling tools, administrative support, and value-based care education, with potential eligibility for Foundational Care™ services.

CVS Health maintains its commitment to value-based care through Oak Street Health®, MinuteClinic®, and Aetna's provider network contracts. Financial terms of the transaction were not disclosed.

CVS Health (NYSE: CVS) has expanded its flu testing and treatment services across select locations. The company has introduced a new 3-in-1 combo test for Influenza A, Influenza B, and COVID-19 at approximately 1,600 locations in 37 states. In 13 states, pharmacists can both test and prescribe antiviral treatment in a single appointment.

The pharmacy-administered combo test costs $29.99, with an additional $45 pharmacist assessment fee. CVS also offers at-home combo test options priced between $12.99 and $24.99. The company provides various delivery options, including same-day and 1-2-day delivery for eligible prescriptions.

Additionally, CVS continues to offer flu and updated 2024-2025 COVID-19 vaccines at CVS Pharmacy and MinuteClinic locations nationwide. Patients 65 and older who received the updated COVID-19 vaccine in fall 2024 are eligible for a second dose after six months.

Thermo Fisher Scientific (NYSE:TMO) has announced the election of Karen S. Lynch to its board of directors, effective February 19, 2025. This appointment increases the board's size to 12 members. Lynch, the former president and CEO of CVS Health , brings over three decades of healthcare industry experience. During her tenure at CVS Health, she led more than 300,000 employees and oversaw operations reaching over 120 million consumers through healthcare benefits, pharmacy benefits management, and 9,000+ community health locations.

Lynch's extensive career includes executive positions at Aetna, Magellan Health Services, and Cigna She began her career as a CPA at Ernst & Young LLP and has served on the boards of CVS Health and U.S. Bancorp.

CVS Health (NYSE: CVS) has appointed Ed DeVaney as president of CVS Caremark, its pharmacy benefit management business, following his interim role since December 2024. DeVaney, who will report to Group President Prem Shah, brings extensive experience from his 20-year tenure with the company.

DeVaney previously led CVS Caremark sales and account management as president of Employer & Health Plans, where he was responsible for growing and maintaining the customer base across PBM lines of business. His role included oversight of government services, coalitions, and the PBM Marketing team.

Prior to joining CVS Health in 2005, DeVaney managed client relationships at Hewitt Associates, specializing in healthcare consulting and benefits administration. His appointment comes with a focus on making prescription drugs more affordable and enhancing drug pricing transparency through innovation.

CVS Health reported Q4 2024 results with total revenues increasing 4.2% to $97.7 billion. Full-year revenues rose 4.2% to $372.8 billion. However, Q4 GAAP diluted EPS decreased to $1.30 from $1.58, and Adjusted EPS fell to $1.19 from $2.12.

The company's Health Care Benefits segment faced challenges, with an adjusted operating loss of $439 million in Q4, compared to income of $676 million in the prior year. This decline was primarily due to increased utilization and unfavorable Medicare Advantage star ratings impact.

For 2025, CVS provided guidance with GAAP diluted EPS range of $4.58 to $4.83, Adjusted EPS of $5.75 to $6.00, and expected cash flow from operations of approximately $6.5 billion.